跳转至内容
Merck
CN

G7048

氯胍 盐酸盐

≥95% (HPLC)

别名:

Chlorguanide, N1-(4-Chlorophenyl)-N5-isopropylbiguanide

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C11H16ClN5·HCl
化学文摘社编号:
分子量:
290.19
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51101906
EC Number:
211-283-7
MDL number:
Assay:
≥95% (HPLC)
Form:
solid
Quality level:
Storage condition:
desiccated
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

Quality Level

assay

≥95% (HPLC)

form

solid

storage condition

desiccated

solubility

acetonitrile: water: ~1 mg/mL (60/40)

originator

AstraZeneca

storage temp.

2-8°C

SMILES string

Cl.CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1

InChI

1S/C11H16ClN5.ClH/c1-7(2)15-10(13)17-11(14)16-9-5-3-8(12)4-6-9;/h3-7H,1-2H3,(H5,13,14,15,16,17);1H

InChI key

SARMGXPVOFNNNG-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

Application

Proguanil (chlorguanide) may be used in anti-parasitic protozoan drug development to study its pharmacokinetics, metabolism, safety, efficacy and methods of delivery as an antimalarial drug.

Biochem/physiol Actions

Chlorguanide (proguanil) is combined with atovaquone for malaria prophylaxis. The two compounds act synergistically to inhibit the plasmodial dihydrofolate reductase (DHFR) and interrupt the electron transport chain. Mutations in DHFR account for the development of resistant strains.
Proguanil hydrochloride is antimalarial. Dihydrofolate reductase inhibitor

Features and Benefits

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Skull and crossbones

signalword

Danger

hcodes

Hazard Classifications

Acute Tox. 3 Oral

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

S Looareesuwan et al.
The American journal of tropical medicine and hygiene, 60(4), 533-541 (1999-05-29)
The continuing spread of drug-resistant malaria emphasizes the need for new antimalarial drugs. Atovaquone is a broad-spectrum antiprotozoal drug with a novel mechanism of action, via inhibition of parasite mitochondrial electron transport, and a favorable safety profile. Early studies with
Sarah Donegan et al.
Statistics in medicine, 31(29), 3840-3857 (2012-07-13)
Mixed treatment comparison (MTC) meta-analysis allows several treatments to be compared in a single analysis while utilising direct and indirect evidence. Treatment by covariate interactions can be included in MTC models to explore how the covariate modifies the treatment effects.
Patricia Schlagenhauf et al.
Expert review of anti-infective therapy, 10(5), 537-546 (2012-06-19)
The concept of 'standby emergency treatment' (SBET) describes the strategy where travelers carry an emergency malaria treatment for self-administration when no medical attention is available or for use under medical supervision after a confirmed malaria diagnosis, and raises many issues
Olivier Bouchaud et al.
Malaria journal, 11, 212-212 (2012-06-23)
Malaria continues to be amongst the most frequent infectious diseases imported to Europe. Whilst European treatment guidelines are based on data from studies carried out in endemic areas, there is a paucity of original prospective treatment data. The objective was
Allan Pamba et al.
Blood, 120(20), 4123-4133 (2012-09-21)
Drug-induced acute hemolytic anemia led to the discovery of G6PD deficiency. However, most clinical data are from isolated case reports. In 2 clinical trials of antimalarial preparations containing dapsone (4,4'-diaminodiphenylsulfone; 2.5 mg/kg once daily for 3 days), 95 G6PD-deficient hemizygous

商品

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

全球贸易项目编号

货号GTIN
G7048-50MG04061833642351
G7048-10MG04061833024195

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持